CCDC91 Inhibitors
Chemical inhibitors of CCDC91 function by disrupting various aspects of the intracellular trafficking process, to which CCDC91 is integral. Wortmannin exerts its inhibitory effect through the blockage of PI3K, a kinase vital for the formation and trafficking of vesicles, which is a key process CCDC91 is associated with. Dynasore targets dynamins, GTPase enzymes necessary for the scission of newly formed vesicles from membranes. This action directly interrupts the vesicle trafficking steps that are crucial for CCDC91 function. Similarly, Chlorpromazine impedes the function of CCDC91 by inhibiting clathrin-mediated endocytosis, a pathway that involves CCDC91 in vesicular sorting and transport. Brefeldin A, on the other hand, disrupts the structure of the Golgi apparatus, through which CCDC91 mediates vesicular movement. This compound's disruption of Golgi function leads to a broad inhibition of vesicle trafficking and thus CCDC91 activity. Monensin interferes with Golgi function as well, but it does so by altering pH and ion gradients, which are essential for the maintenance of Golgi structure and function, and by extension, CCDC91's role in trafficking.
Additionally, Pitstop 2 shuts down CCDC91 function by blocking clathrin-mediated endocytosis, preventing the formation of clathrin-coated vesicles, which are necessary for CCDC91's role in trafficking. Tyrphostin AG 879 and Genistein, both tyrosine kinase inhibitors, inhibit the phosphorylation of key proteins involved in vesicular trafficking pathways that CCDC91 is a part of. Nocodazole and Paclitaxel exert their effects on microtubules, with Nocodazole disrupting microtubule polymerization and Paclitaxel stabilizing microtubules, both leading to the inhibition of CCDC91 by affecting microtubule-dependent vesicle transport. Cytochalasin D inhibits actin polymerization, essential for vesicular motility, and thus impedes CCDC91 function by affecting the cytoskeleton. Lastly, Filipin III binds to cholesterol, disrupting lipid raft formation and function, which is also significant for the vesicular trafficking processes involving CCDC91, affecting membrane curvature and vesicle formation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. PI3K signaling is implicated in vesicular trafficking, and CCDC91 is known to be involved in intracellular trafficking. Inhibition of PI3K can disrupt the vesicle formation and trafficking, thus functionally inhibiting CCDC91. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore is a GTPase inhibitor, specifically targeting dynamin. Since CCDC91 is associated with vesicular trafficking, and dynamins are essential for the scission of vesicles from membranes, Dynasore can interrupt vesicle trafficking, thereby inhibiting the function of CCDC91. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $60.00 $108.00 | 21 | |
Chlorpromazine is known to interfere with clathrin-mediated endocytosis. By inhibiting this process, it can disrupt the endocytic pathway, in which CCDC91 is implicated, subsequently inhibiting the function of CCDC91 in vesicular sorting. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus. Given that CCDC91 is involved in vesicular transport from the Golgi, Brefeldin A can inhibit CCDC91 by disrupting Golgi function and thus vesicle trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering pH and ion gradients. As CCDC91 is involved in trafficking associated with the Golgi, Monensin can inhibit CCDC91 function by perturbing the Golgi's ion balance. | ||||||
Pitstop 2 | 1419093-54-1 | sc-507418 | 10 mg | $360.00 | ||
Pitstop 2 is an inhibitor of clathrin-mediated endocytosis. Since CCDC91 is involved in this specific trafficking pathway, Pitstop 2 can inhibit CCDC91 by blocking the formation of clathrin-coated vesicles. | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
Tyrphostin AG 879 is a tyrosine kinase inhibitor that can disrupt signaling pathways necessary for the proper functioning of vesicular trafficking. As CCDC91 is part of such pathways, this compound can inhibit its function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor, which can inhibit the phosphorylation of proteins involved in vesicular trafficking. Since CCDC91 function is reliant on such signaling, Genistein can inhibit its activity. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which is crucial for vesicle transport processes. Consequently, nocodazole can inhibit CCDC91 by impeding the microtubule-dependent trafficking it facilitates. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Cytochalasin D inhibits actin polymerization, which is essential for maintaining the cytoskeleton and vesicular motility. Disruption of actin dynamics can thus inhibit CCDC91 by affecting vesicle movement and positioning. | ||||||